/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Milestone Pharmaceuticals Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$2.65 -0.0113(-1.13%) MIST at 04 Dec 2025 04:38 PM Biotechnology
Lowest Today 2.525
Highest Today 2.69
Today’s Open 2.69
Prev. Close 2.65
52 Week High 2.77
52 Week Low 0.63
Day’s Range: Low 2.525 High 2.69
52-Week Range: Low 0.63 High 2.77
1 day return -
1 Week return -2.05
1 month return +42.77
3 month return +47.6
6 month return +59.27
1 year return +42.39
3 year return -43.65
5 year return -61.86
10 year return -

Institutional Holdings

Simplify Propel Opportunities ETF 3.33

RTW INVESTMENTS, LLC 2.95

Propel Bio Management LLC 2.11

Alta Fundamental Advisers LLC 1.65

BML Capital Management LLC 1.34

Simplify Asset Management Inc. 1.16

Morgan Stanley - Brokerage Accounts 0.97

The Toronto-Dominion Bank 0.88

Lion Point Capital, LP 0.65

Bleichroeder LP 0.59

UBS Group AG 0.38

XTX Topco Ltd 0.19

Valeo Financial Advisors, LLC 0.15

Goldman Sachs Group Inc 0.14

Cascades Capital Asset Management, LLC 0.08

Susquehanna International Group, LLP 0.07

Northern Trust Corp 0.06

The Colony Group LLC 0.04

Royal Bank of Canada 0.04

Jane Street Group LLC 0.04

Group One Trading, LP 0.04

SPDR® S&P® International Small Cap ETF 0.02

Fidelity Nasdaq Composite Index 0.02

Market Status

Strong Buy: 0

Buy: 2

Hold: 2

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 225.70 M

PB Ratio 11.1753

PE Ratio 0.0

Enterprise Value 203.73 M

Total Assets 75.50 M

Volume 3401066

Company Financials

Annual Revenue FY23:4500000 4.5M, FY22:5000000 5.0M, FY21:15000000 15.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:5000000 5.0M, FY21:15000000 15.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-59251000 -59.3M, FY22:-57134000 -57.1M, FY21:-42633000 -42.6M, FY20:-49967000 -50.0M, FY19:-55229000 -55.2M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:-24999 -0.0M, Q2/2025:-28000 -0.0M, Q1/2025:-27000 -0.0M, Q3/2024:null 0.0M, Q2/2024:-26000 -0.0M

Quarterly Net worth Q3/2025:-11922000 -11.9M, Q2/2025:-12966000 -13.0M, Q1/2025:-20761000 -20.8M, Q3/2024:-9439000 -9.4M, Q2/2024:-9363000 -9.4M

Fund house & investment objective

Company Information Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada.

Organisation Biotechnology

Employees 33

Industry Biotechnology

CEO Mr. Joseph G. Oliveto M.B.A.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow